AstraZeneca (LSE:AZN) recently launched "FluMist Home," an at-home flu vaccine delivery service, marking an important milestone for easier access to vaccinations in 34 U.S. states. This initiative likely contributed to its stock price increase of 12% last quarter,

FluMist has been approved since 2003, but, until last year, only for administration by a healthcare practitioner. The new nod allows adults up to 49 years old to use the nasal spray themselves, while parents and caregivers can give it to children aged 2 to 17.

FluMist is the only nasal vaccine approved in the U.S. It’s administered as two spritzes—one in each nostril—and stimulates antibodies against the influenza virus in the nasal passages and bloodstream to protect against serious disease.